Prne
June 23rd, 2009
CHARLOTTESVILLE, Virginia - Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid.
“We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies,” said Aris Persidis, Ph.D., President of Biovista. “This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company,” added Dr. Persidis.
For a non-confidential information pack on BVA-601, contact Biovista at info@biovista.com.
About Biovista’s BVA-601 trial in the Kainic acid model of epilepsy
Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world’s oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the disorder.
In the animal proof of concept trial, BVA-601 was compared to diazepam, a potent anti-epileptic drug that is efficient in reducing epileptic activity but has troubling adverse events. BVA-601 induced a statistically significant reduction in the number of animals showing epileptic activity and delayed the onset of epileptic seizures.
About Biovista’s repositioning pipeline and technology platform
Biovista applies high-efficiency discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista’s proprietary repositioning technology allows it to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and autoimmune diseases.
Source: Biovista Inc.
Dr. Aris Persidis, +1-434-242-6514, info at biovista.com
Filed under Biotechnology, Business, Clinical Trials / Medical Discoveries, Health, Health Care / Hospitals, Pharmaceuticals, Surveys / Polls / Research | Tags: Biovista Inc., Charlottesville, United States of America, virginia | Comment Below
Related Press Releases Karolinska Development Portfolio Company Completes Successful Phase II Clinical TrialSeptember 3rd, 2009 STOCKHOLM - Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy. D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)August 16th, 2009 REHOVOT, Israel - D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company's late stage clinical stroke program. The financial round combined a rights offering of NIS 57 million and an Initial Public Offering (IPO) of NIS 28 million. Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in NocturiaJune 28th, 2009 SOUTHAMPTON, England - Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly PatientsJune 10th, 2009 SEATTLE - Neurim Pharmaceuticals (www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With GlaucomaMay 5th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA). InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 PatientsMay 5th, 2009 TEL AVIV, Israel - InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the iMOS registry. MGuard(TM) was successfully implanted at the General University Hospital in Prague; the procedure was performed by Dr. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke PatientsMay 5th, 2009 REHOVOT, Israel - D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar ABMay 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry EyeApril 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome. BioCis Pharma Starts Phase IIa Trial in PsoriasisMarch 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis.
Related News Fast acting erectile disorder drug goes on trial againFebruary 15th, 2009 WASHINGTON - A new fast-acting oral drug for erectile dysfunction (ED) is ready for a crucial trial phase. It's going to be a multicentre, randomised, double-blind, placebo-controlled trial that will evaluate the safety and efficacy of Avanafil in the treatment of ED in men with type-1 or type-2 diabetes. New device may make menstrual cramp pain 'history'September 22nd, 2009 WASHINGTON - For women who experience severe menstrual pain, a new device developed by University of Cincinnati researchers could appear as a blessing. Fed up of the chronic pain, women often end up having medications that can cause gastrointestinal side effects. MakroCare announces workshop on Advanced GCP on May 15May 6th, 2009 HYDERABAD - MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries, is taking a lead in the training of professionals for the clinical research industry by providing series of informational through workshop and seminars. Advanced GCP workshop will be held at CHITRAMAYEE Auditorium, State Arts Gallery, Kavuri Hills, Madhapur, Hyderabad on May 15. "Male Pill" can provide effective contraceptionMay 5th, 2009 WASHINGTON - A "male Pill" tested by scientists has proved to be as good as its female equivalent after a major study found only one in 100 males using the injections conceived a child. According to researchers, the testosterone injection could revolutionise family planning methods. Novel target for migraine prevention identifiedApril 29th, 2009 WASHINGTON - Researchers have found a potential target for developing new treatment for acute migraine attacks. The new research by Addex Pharmaceuticals showed that targeting glutamate receptor 'mGluR5', the most common neurotransmitter in the brain, could prevent migraines. Injectable testosterone - way to effective male contraceptionMay 5th, 2009 WASHINGTON - Injectable testosterone could be the way to male contraception, that is effective, reversible, and minus serious short-term side-effects, according to a new study. 'For couples who can not, or prefer not to, use only female-oriented contraception, options have been limited to vasectomy, condom and withdrawal,' said Yi-Qun Gu, National Research Institute for Family Planning (NRIFP) in Beijing. Catalyst says it sees evidence its drug vigabatrin is effective despite failures; study surgesOctober 1st, 2009 Catalyst plans more tests of anti-addiction drugNEW YORK — Catalyst Pharmaceutical Partners Inc. says it will continue developing an anti-addiction drug that has failed in two clinical trials, as it believes the treatment is safe and effective. Oral migraine therapy effective in providing reliefAugust 12th, 2009 WASHINGTON - A new investigational, orally inhaled therapy has been found effective in treating migraines, according to researchers. The research team from Thomas Jefferson University Hospital in Philadelphia, Pennsylvania have shown that LEVADEX provided pain relief in 30 minutes and sustained relief for 48 hours. Developmental drug effective against radiation damageApril 23rd, 2009 WASHINGTON - A drug, currently under development, has been found effective in providing protection against damaging effects of radiation exposure. The research team from University of Pittsburgh School of Medicine has found that experimental drug JP4-039 protects cells from being damaged by radiation exposure. Contrave - Weight-Loss Drug Trials Meet GoalsJuly 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss
in three late-stage clinical trials according to Associated Press reports.
|
|
